DAWN
Day One Biopharmaceuticals I
NASDAQ · Biotechnology
$11.41
+0.93 (+8.87%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 148.71M | 322.81M | 330.87M | 292.97M |
| Net Income | -108,273,267 | -68,873,512 | -86,473,457 | -66,837,013 |
| EPS | — | — | — | — |
| Profit Margin | -72.8% | -21.3% | -26.1% | -22.8% |
| Rev Growth | — | +3.3% | -3.7% | -9.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 233.47M | 239.68M | 231.49M |
| Total Equity | — | 409.99M | 453.69M | 388.91M |
| D/E Ratio | — | 0.57 | 0.53 | 0.60 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -122,405,978 | -92,549,420 | -89,278,899 | -77,082,109 |
| Free Cash Flow | — | -81,242,335 | -91,466,852 | -93,667,658 |